Some weight-loss and diabetes drugs can treat obesity when combined with exercise, a healthy diet, and counseling, according to WHO's first guidance on these medicines. The recommendations come amid ...

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

Congress has the power to make obesity treatment and weight management accessible to the communities that need it.

Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients ...

The SURMOUNT-1 trial evaluated Tirzepatide a dual GIP/GLP1 agonist, in individuals with overweight (BMI more than or equal to ...

Trials have shown that semaglutide can reduce major cardiovascular events, but the extent of tirzepatide’s heart protection has been less clear. A team at Mass General Brigham set out to compare both ...

Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a ...

The five-year SURMOUNT-REAL UK trial, part of a collaboration signed last year between Lilly and the UK government, will ...

Love Is Blind alum Irina Solomonova has been using a GLP-1 to slim down. “I’m finishing my first month on GLP-1s. I’m on ...